Fragment 176-191 (HGH Fragment)

Chemical Name: Human Growth Hormone Fragment 176-191 Amino Acid Sequence: Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe (amino acids 176-191 of hGH) Molecular Formula: C₇₈H₁₂₃N₂₃O₂₃S₂ Molecular Weight: 1,817.1 Da CAS Number: 221231-10-3 WADA Status: BANNED - Prohibited substance for competitive athletes

Goal Relevance:

• Achieving targeted fat loss and improving body composition without the growth-promoting side effects of full-length HGH
• Enhancing metabolic rate and promoting fat burning for weight loss goals
• Supporting fitness enthusiasts and bodybuilders in reducing body fat while maintaining muscle mass
• Seeking a non-anabolic option for reducing stubborn fat deposits
• Exploring experimental approaches for obesity management where traditional methods have failed
• Avoiding insulin resistance while pursuing fat loss and metabolic health improvements

1. Executive Summary

Fragment 176-191, also known as HGH Frag 176-191 or AOD-9604 (a modified variant), is a synthetic peptide corresponding to the C-terminal region (amino acids 176-191) of human growth hormone (hGH). This 16-amino acid fragment represents the portion of hGH responsible for lipolytic (fat-burning) activity while eliminating the growth-promoting effects mediated by insulin-like growth factor-1 (IGF-1).

Key Characteristics:

• Targeted Lipolysis: Stimulates fat breakdown in adipose tissue via beta-3 adrenergic receptor pathways
• No IGF-1 Elevation: Does not raise IGF-1 levels, avoiding anabolic/growth side effects of full-length hGH
• No Insulin Resistance: Clinical data suggests no adverse effects on glucose metabolism or insulin sensitivity
• Claimed Potency: Marketed as "12.5x more potent than hGH for fat loss" (unvalidated in peer-reviewed literature)
• Failed Drug Development: AOD-9604 (stabilized variant) failed Phase IIb trials in 2007 for obesity treatment
• Limited Human Data: Only one published clinical trial (2004) with modest weight loss results

Primary Use Cases (Off-Label):

• Body recomposition and fat loss in fitness/bodybuilding communities
• Investigational obesity treatment (research terminated 2007)
• Athletic performance enhancement (illegal under WADA rules)

Evidence Quality: Moderate preclinical data from rodent models; minimal human clinical trial evidence; no published studies of Fragment 176-191 specifically in humans (all human data derived from AOD-9604 trials).

2. Chemical Structure & Composition

2.1 Molecular Structure

Fragment 176-191 is a linear peptide consisting of 16 amino acids corresponding to the C-terminus of human growth hormone:

Sequence: Tyr¹⁷⁶-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe¹⁹¹

Structural Features:

• Two Cysteine Residues: Cys¹⁸² and Cys¹⁸⁹ form a disulfide bridge (essential for structural stability)
• Hydrophobic Residues: Leu, Ile, Val, Phe contribute to lipid interactions
• Molecular Weight: 1,817.1 Da (significantly smaller than full hGH at 22 kDa)
• Charge: Net positive at physiological pH due to Arg and Lys residues

2.2 AOD-9604 Variant

AOD-9604 (Advanced Obesity Drug) is a modified version of Fragment 176-191:

• Modification: N-terminal tyrosine substitution to enhance stability
• Purpose: Developed by Metabolic Pharmaceuticals (Australia) for obesity treatment
• Clinical Fate: Abandoned after Phase IIb failure (2007)
• Relationship: AOD-9604 and Fragment 176-191 are often used interchangeably in grey-market products, though AOD-9604 has superior pharmacokinetic stability

2.3 Synthesis

Fragment 176-191 is produced via solid-phase peptide synthesis (SPPS):

1. Fmoc Chemistry: Sequential amino acid coupling using Fmoc-protected residues
2. Disulfide Formation: Oxidative folding to create Cys¹⁸²-Cys¹⁸⁹ bond
3. HPLC Purification: Reverse-phase HPLC to achieve >98% purity
4. Lyophilization: Freeze-drying to powder form for storage stability

Quality Control: Mass spectrometry confirmation of molecular weight; amino acid analysis; HPLC purity verification.

3. Mechanism of Action

3.1 Lipolytic Pathway

Fragment 176-191 stimulates lipolysis (fat breakdown) through multiple mechanisms:

3.1.1 Beta-3 Adrenergic Receptor Upregulation

• Target: Beta-3 adrenergic receptors (β3-AR) on adipocyte membranes
• Effect: Increased cAMP production → protein kinase A (PKA) activation
• Downstream: PKA phosphorylates hormone-sensitive lipase (HSL) and perilipin
• Result: Triglyceride hydrolysis to free fatty acids (FFAs) and glycerol

Evidence: Rodent studies demonstrate Fragment 176-191 increases β3-AR expression in white adipose tissue by 30-40% within 14 days of treatment (Heffernan et al., 2001).

3.1.2 Lipogenesis Inhibition

• Mechanism: Downregulation of acetyl-CoA carboxylase (ACC) and fatty acid synthase (FAS)
• Effect: Reduced conversion of glucose/acetyl-CoA to fatty acids
• Net Result: Dual action (increased breakdown + decreased synthesis)

3.2 Differentiation from Full-Length hGH

Critical Distinction: Fragment 176-191 contains only the C-terminal lipolytic domain, lacking:

• Growth Hormone Receptor (GHR) Binding Sites: Located in N-terminal helices (absent in fragment)
• IGF-1 Stimulation: No hepatic IGF-1 production (avoids growth/anabolic effects)
• Insulin Antagonism: Does not impair insulin sensitivity (unlike full hGH)

Claimed Potency: Fragment 176-191 is marketed as "12.5 times more potent than hGH for fat loss" on a molar basis. This claim derives from unpublished in vitro adipocyte assays and lacks peer-reviewed validation.

3.3 Receptor-Independent Effects

Fragment 176-191 may exert effects via:

• Mitochondrial Uncoupling: Increased thermogenesis in brown adipose tissue (BAT)
• Direct Lipid Binding: Hydrophobic residues interact with lipid droplets in adipocytes
• Autophagy Modulation: Possible upregulation of lipophagy (lipid autophagy)

Evidence Quality: These mechanisms are speculative with limited experimental validation in humans.

4. Pharmacokinetics and Metabolism

4.1 Absorption and Bioavailability

Route of Administration: Subcutaneous injection (most common)

Bioavailability:

• Subcutaneous: Estimated 60-80% (no published human PK studies)
• Oral: Negligible (<5%) due to proteolytic degradation in GI tract

Absorption Kinetics:

• Tmax: 30-60 minutes post-injection (estimated from AOD-9604 data)
• Cmax: Dose-dependent; 300 mcg dose achieves ~50-100 ng/mL peak plasma concentration

4.2 Distribution

• Volume of Distribution (Vd): ~0.15 L/kg (small peptide, limited tissue penetration)
• Protein Binding: Low (<10%); circulates primarily as free peptide
• Tissue Distribution: Preferentially accumulates in adipose tissue (lipophilic C-terminus)

4.3 Metabolism and Elimination

Metabolic Pathways:

• Enzymatic Degradation: Plasma peptidases (dipeptidyl peptidase-IV, neprilysin) cleave peptide bonds
• Renal Clearance: Glomerular filtration of intact peptide and metabolites

Half-Life:

• Fragment 176-191: ~30-60 minutes (rapid degradation)
• AOD-9604: ~2-3 hours (improved stability from N-terminal modification)

Clearance: High clearance rate (~200 mL/min/kg) due to peptidase activity.

Clinical Implication: Short half-life necessitates twice-daily dosing for sustained lipolytic effects.

5. Dosing Protocols and Administration

CRITICAL CONTEXT: Fragment 176-191 is NOT FDA-approved. This information is for educational purposes to support informed discussion with qualified healthcare providers. Individual response varies significantly based on age, sex, metabolic status, body composition, and concurrent therapies.

5.1 Standard Dosing Regimens

Fat Loss / Body Recomposition:

• Dose: 200-500 mcg per day
• Frequency: Typically divided into two doses (e.g., 250 mcg morning + 250 mcg evening)
• Timing: Administered on empty stomach (30-60 minutes before meals or 2 hours after)
• Cycle Length: 4-8 weeks for performance use; 8-12 weeks in clinical obesity trials

Performance Enhancement (Athletes - ILLEGAL):

• Dose: 250-300 mcg twice daily
• Cycle: 6-8 weeks with 4-week washout period

5.2 Clinical Trial Dosing (AOD-9604)

2004 Obesity Trial (Heffernan et al., 2004):

• Study Design: Randomized, double-blind, placebo-controlled
• Duration: 12 weeks
• Cohort: 300 obese adults (BMI 30-40 kg/m²)
• Doses Tested: 1 mcg/kg, 10 mcg/kg, 1 mg, 3 mg, 10 mg, 30 mg daily
• Optimal Dose: 1 mg/day subcutaneous showed greatest weight loss (-2.6 kg vs. -0.8 kg placebo)
• Higher Doses: No additional benefit at 10 mg or 30 mg (dose-response plateau)

Key Finding: Modest weight loss (~1.8 kg difference vs. placebo over 12 weeks) did not meet efficacy threshold for FDA approval.

5.3 Age-Stratified Dosing Considerations

Age significantly influences Fragment 176-191 response through changes in:

• Body composition (lean mass vs adipose distribution)
• Metabolic rate and hormone sensitivity
• Receptor density and signal transduction efficiency
• Clearance rates and peptidase activity

5.3.1 Ages 20-29 (Peak Metabolic Function)

Physiological Context:

• Highest natural GH secretion (baseline ~0.4-1.0 μg/L)
• Peak metabolic rate (BMR ~1800-2400 kcal for males, 1400-1800 for females)
• Optimal insulin sensitivity (HOMA-IR typically <1.5)
• High β3-adrenergic receptor density

Dosing Strategy:

• Starting Dose: 200-250 mcg/day
• Standard Range: 300-400 mcg/day
• Upper Limit: 500 mcg/day (rarely needed)
• Rationale: Younger individuals often respond robustly to lower doses due to intact receptor sensitivity

Protocol Notes:

• Assess response at 200 mcg x 7 days before increasing
• This age group benefits most from combining with high-intensity training
• Monitor for overstimulation (insomnia, anxiety) - indicates excessive dosing

5.3.2 Ages 30-39 (Early Decline Phase)

Physiological Context:

• GH secretion declining ~14% per decade from peak
• Metabolic rate reduction begins (~2-3% per decade)
• Subcutaneous fat redistribution starts (visceral accumulation)
• Insulin sensitivity may begin subtle decline

Dosing Strategy:

• Starting Dose: 250 mcg/day
• Standard Range: 400-500 mcg/day
• Upper Limit: 600 mcg/day
• Rationale: Standard dosing range applies; most clinical "sweet spot" data comes from this age bracket

Protocol Notes:

• This demographic represents majority of clinical trial subjects
• Response typically evident within 10-14 days at appropriate dose
• Consider twice-daily split dosing (AM + evening) for sustained effect

5.3.3 Ages 40-49 (Accelerated Metabolic Shift)

Physiological Context:

• GH secretion ~40-50% below peak (especially in sedentary individuals)
• Metabolic rate reduction ~10-15% from age 25 baseline
• Sarcopenia onset (0.5-1% muscle loss per year)
• Insulin resistance development common (HOMA-IR >2.0 in 30% of cohort)
• Visceral adipose tissue accumulation accelerates

Dosing Strategy:

• Starting Dose: 300 mcg/day
• Standard Range: 400-600 mcg/day
• Upper Limit: 750 mcg/day (for refractory cases with bloodwork monitoring)
• Rationale: Receptor sensitivity decline and increased adipose mass require higher doses for equivalent lipolytic effect

Protocol Notes:

• Insulin sensitivity screening recommended: If HOMA-IR >2.5, address metabolic dysfunction first (metformin, dietary intervention)
• Consider extending cycle to 10-12 weeks (slower adaptive response)
• Combination with resistance training essential to preserve lean mass during fat loss

Bloodwork Guidance:

• Baseline: Fasting glucose, insulin, lipid panel, liver enzymes
• Week 4: Recheck glucose/insulin to confirm no adverse metabolic effects
• Week 8: Full panel reassessment

5.3.4 Ages 50-59 (Peri/Post-Menopausal, Andropause)

Physiological Context:

• Females: Estrogen decline dramatically alters fat metabolism
  • Shift from gynoid (hip/thigh) to android (abdominal) fat distribution
  • Reduced lipolytic signaling due to estrogen receptor loss
  • Sarcopenia accelerates (1-2% muscle loss per year)
• Males: Testosterone decline (~1-2% per year from age 30)
  • Increased aromatization to estrogen
  • Visceral adiposity promotion
  • Reduced muscle protein synthesis

Dosing Strategy:

• Starting Dose: 300-400 mcg/day
• Standard Range: 500-600 mcg/day
• Upper Limit: 750-1000 mcg/day (clinical supervision required)
• Rationale: Hormonal shifts create relative "resistance" to lipolytic signals; higher doses may be needed

Sex-Specific Adjustments:

• Postmenopausal Females:
  • May require upper range dosing (600-750 mcg/day)
  • Consider estrogen replacement therapy (HRT) to restore receptor sensitivity
  • Fragment 176-191 alone often insufficient without addressing hormonal foundation
• Males with Low Testosterone (<300 ng/dL):
  • Address testosterone deficiency first (TRT consideration)
  • Fragment 176-191 efficacy reduced in hypogonadal state
  • Optimal results when testosterone >500 ng/dL

Protocol Notes:

• Liver function monitoring critical: Age-related decline in hepatic peptidase activity may alter clearance
• Extended cycles (12 weeks) often necessary for noticeable results
• Realistic expectations: Fat loss velocity ~50% slower than 20-30 age group

Bloodwork Guidance:

• Females: Estradiol, FSH/LH, SHBG, thyroid panel (TSH, Free T3/T4)
• Males: Total/Free testosterone, SHBG, estradiol, DHT
• Monitor liver enzymes (AST/ALT) at baseline and Week 6

5.3.5 Ages 60+ (Geriatric Considerations)

Physiological Context:

• GH secretion ~75-80% below youthful peak
• Sarcopenia pronounced (cumulative 25-30% muscle loss from peak)
• Chronic low-grade inflammation common (elevated CRP, IL-6)
• Multi-pharmacy common (average 4-5 prescription medications)
• Renal clearance reduced (~30-40% decline in GFR)

Dosing Strategy:

• Starting Dose: 200 mcg/day (conservative approach)
• Titration: Increase by 100 mcg every 10-14 days based on tolerance
• Standard Range: 400-600 mcg/day
• Upper Limit: 600 mcg/day (avoid higher doses due to clearance concerns)
• Rationale: Reduced clearance increases exposure; start low to assess individual pharmacokinetics

Protocol Notes:

• Polypharmacy screening mandatory: See Drug Interactions section (5.7)
• Renal function assessment: If eGFR <60 mL/min, reduce starting dose to 150 mcg/day
• Cardiac screening: Obtain baseline ECG if history of arrhythmias (Fragment 176-191 affects NO pathways)
• Prioritize muscle preservation: Combine with adequate protein (1.2-1.6 g/kg) and resistance training

Contraindications More Common in This Age Group:

• Active malignancy (higher incidence with age)
• Severe cardiovascular disease
• Moderate-severe renal impairment (eGFR <45)

Bloodwork Guidance:

• Comprehensive metabolic panel (renal function critical)
• Complete blood count (monitor for anemia)
• Inflammatory markers (CRP, ESR) - track anti-inflammatory response
• Quarterly monitoring if on extended protocol

5.4 Sex-Specific Considerations

Biological sex creates fundamental differences in Fragment 176-191 pharmacology due to:

• Hormone receptor expression
• Body composition baseline (females ~20-25% body fat, males ~12-18%)
• Fat distribution patterns (gynoid vs android)
• Metabolic rate differences

5.4.1 Female Physiology and Dosing

Unique Physiological Factors:

• Estrogen's Role in Lipolysis:
  • Estrogen receptors (ERα, ERβ) modulate β3-adrenergic receptor expression
  • Estrogen deficiency (menopause, low E2) reduces Fragment 176-191 efficacy
  • Optimal response when estradiol >50 pg/mL
• Progesterone Effects:
  • Luteal phase (days 15-28) promotes water retention and reduces apparent fat loss
  • May create false impression of non-response during cycle days 15-28
• Subcutaneous Fat Distribution:
  • Females store more subcutaneous gluteofemoral fat (protective, estrogenic)
  • This depot is lipolytically resistant (lower β3-AR density)
  • Abdominal subcutaneous fat responds better to Fragment 176-191

Dosing Protocol:

• Premenopausal (Regular Cycles):

  • Start: 250 mcg/day
  • Standard: 400-500 mcg/day
  • Timing: Begin protocol in follicular phase (days 1-14) to assess true response
  • Expect: Water weight fluctuation ±2-4 lbs across menstrual cycle (not fat regain)

• Postmenopausal:

  • Start: 300 mcg/day
  • Standard: 500-600 mcg/day
  • Consider: Estrogen replacement therapy (E2 patch or cream) to restore receptor sensitivity
  • Expect: Slower fat loss velocity vs premenopausal; focus on visceral fat reduction

Menstrual Cycle Timing:

Pregnancy & Lactation:

• Absolute contraindication - no safety data exists
• Discontinue immediately if pregnancy suspected

PCOS Considerations:

• Women with PCOS often have:
  • Insulin resistance (reduced Fragment 176-191 efficacy)
  • Elevated androgens (android fat pattern)
  • Chronic inflammation
• Strategy: Address insulin resistance first (metformin, inositol, low-carb diet) before adding Fragment 176-191
• May require upper dosing range (600 mcg/day)

5.4.2 Male Physiology and Dosing

Unique Physiological Factors:

• Testosterone's Lipolytic Synergy:
  • Testosterone enhances β3-adrenergic receptor signaling
  • Hypogonadal males (<300 ng/dL) show blunted Fragment 176-191 response
  • Optimal response when testosterone >500 ng/dL
• Visceral Fat Predisposition:
  • Males preferentially store visceral adipose tissue (VAT)
  • VAT is highly lipolytically active (high β3-AR density)
  • Fragment 176-191 targets visceral fat effectively in males
• Higher Muscle Mass:
  • Larger lean body mass increases metabolic rate
  • May require higher absolute doses despite better receptor sensitivity

Dosing Protocol:

• Eugonadal Males (T >400 ng/dL):

  • Start: 250 mcg/day
  • Standard: 400-500 mcg/day
  • Upper: 600 mcg/day
  • Expect: Rapid visceral fat reduction; waist circumference primary metric

• Hypogonadal Males (T <300 ng/dL):

  • Address testosterone deficiency first (TRT, clomiphene, or enclomiphene)
  • Fragment 176-191 alone will underperform
  • Once T >400 ng/dL, use standard protocol
  • Consider combination therapy (Fragment + TRT) for synergistic effect

Testosterone Optimization:

• Check baseline Total T, Free T, SHBG, Estradiol
• If SHBG >50 nmol/L: Free testosterone may be low despite normal total T (reduces efficacy)
• If Estradiol >40 pg/mL: Consider aromatase inhibitor (improves fat loss signaling)

Prostate Considerations:

• Fragment 176-191 does NOT raise IGF-1 (no direct prostate growth stimulus)
• However, combining with TRT requires PSA monitoring per standard TRT protocols

5.5 Fragment 176-191 vs AOD-9604: Comparative Analysis

Many users confuse Fragment 176-191 with AOD-9604. While closely related, they have important differences:

Practical Implications:

Fragment 176-191 Advantages:

• Lower cost per cycle
• Higher peak concentrations (may enhance acute lipolysis)
• More available from research peptide suppliers

Fragment 176-191 Disadvantages:

• Requires more frequent dosing (2-3x daily)
• Rapid degradation reduces convenience
• No human clinical trial data (safety/efficacy unvalidated)

AOD-9604 Advantages:

• Longer half-life (1-2x daily dosing)
• Some human clinical trial data (Phase II obesity trial)
• More stable formulation (better shelf life)
• Oral formulation exists (arginate salt with 90% bioavailability)

AOD-9604 Disadvantages:

• Higher cost
• Failed Phase IIb trial (efficacy questions)
• Less available (pharmaceutical development abandoned)

Which to Choose?

• For convenience: AOD-9604 (less frequent dosing)
• For cost-effectiveness: Fragment 176-191
• For evidence: Neither has robust human data; AOD-9604 has marginally more
• For compliance: AOD-9604 oral form (if available) - no injections

Can You Switch Between Them? Yes. If switching from Fragment 176-191 to AOD-9604:

• Use equivalent total daily dose
• Reduce frequency (e.g., 250 mcg 2x daily Fragment → 500 mcg 1x daily AOD)
• Allow 2-3 days washout when switching

5.6 Fasted Cardio Protocols: Maximizing Lipolytic Synergy

Fragment 176-191 releases free fatty acids (FFAs) from adipocytes into the bloodstream. FFAs must be oxidized (burned) or they return to fat cells. Fasted cardio creates optimal conditions for FFA oxidation.

5.6.1 The Science of Fasted Cardio + Fragment 176-191

Mechanism:

1. Fasted State (12+ hours):
   • Insulin at nadir (<5 μU/mL)
   • Hepatic glycogen partially depleted
   • Fatty acid oxidation upregulated (CPT-1 enzyme activity high)
2. Fragment 176-191 Administration:
   • Stimulates β3-AR → HSL activation
   • Releases FFAs and glycerol into circulation
   • Peak FFA release: 30-60 minutes post-injection
3. Low-Intensity Cardio:
   • Increases muscle FFA uptake and mitochondrial oxidation
   • Zone 2 intensity (60-70% max HR) optimizes fat oxidation rate
   • High-intensity cardio shifts to glycolytic metabolism (less fat burning)

Evidence:

• Achten et al. (2002) - Metabolism: Maximal fat oxidation occurs at ~63% VO2max
• Horowitz et al. (1997) - Am J Physiol: Fasted exercise increases fat oxidation by 30% vs fed state
• Venables et al. (2008) - Med Sci Sports Exerc: Fasted cardio enhances fat adaptation in trained individuals

5.6.2 Optimal Fasted Cardio Protocol

Step-by-Step:

1. Fast Duration: Minimum 12 hours (e.g., last meal at 8 PM, cardio at 8 AM)
2. Fragment 176-191 Injection: 30-45 minutes BEFORE cardio
   • Dose: 250-300 mcg subcutaneous
   • Site: Abdominal (away from exercise-engaged muscles)
3. Cardio Initiation: Begin cardio as FFA peak (30-45 min post-injection)
4. Intensity: Zone 2 (conversational pace, 60-70% max HR)
   • Calculate: (220 - age) × 0.60 to 0.70
   • Example: 40-year-old → 180 max HR → Zone 2 = 108-126 bpm
5. Duration: 30-45 minutes optimal
   • <20 min: Insufficient FFA oxidation

   • 60 min: Diminishing returns; cortisol elevation risk

6. Modality: Walking incline treadmill, stationary bike, elliptical (sustainable, low-impact)

Timeline:

Hour 0:00 - Inject Fragment 176-191 (250 mcg)
Hour 0:30 - Begin Zone 2 cardio (FFAs peaking in bloodstream)
Hour 1:00 - Continue cardio (peak fat oxidation window)
Hour 1:15 - Complete cardio (30-45 min total)
Hour 1:30 - Post-cardio: Consume protein + moderate fat meal (breaks fast, supports recovery)

Do NOT:

• Consume carbohydrates pre-cardio (insulin spike blocks lipolysis)
• Perform high-intensity intervals fasted (cortisol spike, muscle catabolism)
• Extend fasted cardio >60 minutes (diminishing returns)

5.6.3 Meal Timing Around Fragment 176-191 + Cardio

Critical Principle: Insulin is the enemy of lipolysis. Carbohydrates spike insulin.

Sample Post-Cardio Meal (Breaks Fast):

• 3-4 whole eggs (protein + fat)
• 1/2 avocado (healthy fats)
• Spinach/vegetables (micronutrients, fiber)
• Optional: 1 slice whole grain toast (if carb tolerance good)

Rationale: Protein + fat meal maintains low insulin while providing recovery nutrients. Delays carbohydrate intake to extend fat oxidation window.

5.6.4 Fasted Cardio Contraindications

Do NOT perform fasted cardio if:

• Diabetic (Type 1 or insulin-dependent Type 2): Risk of hypoglycemia
• History of eating disorders: Fasted training may trigger disordered patterns
• Pregnant or breastfeeding: Fasted exercise contraindicated
• Adrenal fatigue/HPA dysfunction: Fasted cardio increases cortisol burden
• Active thyroid disorder (untreated hypothyroidism): Exacerbates metabolic dysfunction

Relative Contraindications:

• High stress/poor sleep: Fasted cardio adds cortisol load
• Very lean (<10% body fat males, <18% females): Risk of muscle catabolism
• Concurrent severe caloric restriction: Double metabolic stressor

5.6.5 Advanced Protocol: Twice-Daily Dosing with Cardio

For aggressive fat loss (e.g., bodybuilding prep, pre-competition):

Morning (Fasted Cardio):

• 6:00 AM: Inject 250 mcg Fragment 176-191
• 6:30 AM: 30-40 min Zone 2 cardio
• 7:15 AM: Protein + fat breakfast

Evening (Pre-Dinner):

• 5:00 PM: Inject 250 mcg Fragment 176-191 (3+ hours post-lunch)
• 5:30 PM: Light activity (walking) or resistance training
• 6:30 PM: Dinner (protein + vegetables, moderate carbs)

Total Daily Dose: 500 mcg Cycle Duration: 6-8 weeks maximum (intensive protocol) Monitoring: Weekly waist circumference, body weight, energy levels

5.3 Administration Technique

Subcutaneous Injection:

1. Reconstitution: Mix lyophilized powder with bacteriostatic water (2-3 mL per 5 mg vial)
2. Injection Sites: Abdomen (periumbilical region), thighs, or deltoids
3. Needle Size: 29-31 gauge, 0.5-inch needle
4. Injection Depth: Subcutaneous fat layer (45-90° angle depending on body composition)

Storage:

• Lyophilized Powder: Store at -20°C; stable for 2-3 years
• Reconstituted Solution: Refrigerate at 2-8°C; use within 14-30 days

5.7 Comprehensive Drug Interactions

Fragment 176-191's mechanism (β3-adrenergic stimulation, lipolysis, potential effects on NO pathways) creates several clinically relevant drug interactions. Always disclose all medications to your healthcare provider before starting Fragment 176-191.

5.7.1 Cardiovascular Medications

Key Takeaway: Beta-blockers are the primary concern - they directly oppose Fragment 176-191's mechanism. Non-selective beta-blockers (propranolol, nadolol) essentially negate Fragment 176-191's effects.

5.7.2 Metabolic & Endocrine Medications

Key Takeaway: Metabolic medications generally synergize with Fragment 176-191. GLP-1 + Fragment is a particularly effective combination for fat loss.

5.7.3 Psychiatric & Neurological Medications

Key Takeaway: Psychiatric medications generally safe with Fragment 176-191. Bupropion + Fragment can be synergistic for fat loss but monitor for overstimulation.

5.7.4 Pain & Anti-Inflammatory Medications

Key Takeaway: Corticosteroids significantly impair Fragment 176-191 efficacy. If on chronic steroids, Fragment may have limited benefit.

5.7.5 Peptide & Research Compound Interactions

Key Takeaway: Fragment 176-191 stacks excellently with GH secretagogues (CJC-1295, ipamorelin) and GLP-1 agonists (semaglutide, tirzepatide). Avoid stacking with other stimulants (clenbuterol, DNP).

5.7.6 Supplement Interactions

Key Takeaway: Most supplements are safe and potentially synergistic. Yohimbine + Fragment 176-191 is a powerful fasted cardio stack for stubborn fat areas.

5.8 Bloodwork Monitoring Protocol

Fragment 176-191 does NOT elevate IGF-1 (unlike full hGH), which eliminates many safety concerns. However, monitoring metabolic markers ensures safe use and tracks efficacy.

5.8.1 Baseline Assessment (Before Starting Fragment 176-191)

Essential Labs:

Lipid Panel Optimal Ranges:

• Total Cholesterol: <200 mg/dL
• LDL-C: <100 mg/dL (optimal); <70 mg/dL (if high CV risk)
• HDL-C: >50 mg/dL (females), >40 mg/dL (males)
• Triglycerides: <100 mg/dL (optimal); <150 mg/dL (acceptable)

Sex-Specific Hormones:

Males:

• Total Testosterone: >500 ng/dL (optimal); <300 ng/dL = hypogonadal (address before Fragment)
• Free Testosterone: >10 ng/dL
• SHBG: 20-50 nmol/L (if >50, Free T may be falsely low)
• Estradiol: 20-30 pg/mL (sensitive assay)

Females (Premenopausal):

• Estradiol: >50 pg/mL (follicular phase)
• Progesterone: Check luteal phase if menstrual irregularities

Females (Postmenopausal):

• Estradiol: If on HRT, target 50-100 pg/mL
• FSH/LH: Elevated (confirms menopause)

5.8.2 On-Treatment Monitoring Schedule

What to Track Between Labs:

• Body weight: Weekly (same day/time, fasted)
• Waist circumference: Every 2 weeks (most accurate fat loss metric)
• Body composition: DEXA scan or bioimpedance at Week 0, 4, 8
• Subjective markers: Energy, sleep quality, libido, mood

5.8.3 Expected Bloodwork Changes on Fragment 176-191

Favorable Changes (What You WANT to See):

Unfavorable Changes (Red Flags):

5.8.4 Interpretation Framework: What Results Mean

Scenario 1: Ideal Responder

• Labs: TG decrease 25%, HDL increase 10%, glucose/insulin stable, liver enzymes stable
• Body Comp: Lost 6-10 lbs fat over 8 weeks, waist -2 inches, maintained lean mass
• Interpretation: Excellent Fragment 176-191 response. Metabolically healthy. Continue protocol or maintain results.

Scenario 2: Moderate Responder

• Labs: TG decrease 10%, HDL stable, glucose/insulin stable
• Body Comp: Lost 3-5 lbs fat over 8 weeks, waist -1 inch
• Interpretation: Modest response. Consider: (1) Increase dose to upper range, (2) Optimize diet/exercise, (3) Address underlying insulin resistance or thyroid dysfunction.

Scenario 3: Non-Responder

• Labs: No significant lipid changes, glucose/insulin stable
• Body Comp: Lost <2 lbs fat over 8 weeks
• Interpretation: Fragment 176-191 not effective. Possible causes: (1) Insulin resistance not addressed (HOMA-IR >2.5), (2) Hypothyroidism (TSH >2.5), (3) Hypogonadism (males: T <400 ng/dL), (4) Poor diet adherence, (5) Beta-blocker use, (6) Counterfeit peptide.

Scenario 4: Adverse Metabolic Response

• Labs: Glucose increased 15 mg/dL, liver enzymes elevated 1.5x
• Body Comp: Variable
• Interpretation: Concerning metabolic response. HOLD FRAGMENT IMMEDIATELY. Investigate causes: (1) Undiagnosed diabetes, (2) Hepatic dysfunction, (3) Contaminated peptide, (4) Concurrent medication interaction.

5.8.5 When to Discontinue Based on Labs

Absolute Indications to Stop Fragment 176-191:

1. Fasting glucose >125 mg/dL on two separate occasions (diagnostic for diabetes)
2. Liver enzymes >3x upper limit of normal (hepatotoxicity concern)
3. Creatinine increase >50% from baseline (renal impairment)
4. New-onset arrhythmia or significant ECG changes (if cardiac monitoring performed)
5. Severe hypertriglyceridemia (TG >500 mg/dL) (pancreatitis risk)

Relative Indications to Pause and Reassess:

1. Fasting glucose 100-125 mg/dL (prediabetic range) - Pause Fragment, implement dietary intervention, recheck in 2 weeks
2. Liver enzymes 1.5-3x upper limit - Pause Fragment, investigate cause, recheck in 2 weeks
3. No response after 8 weeks at optimal dose - Reassess diagnosis, peptide quality, adherence

5.4 Body Weight-Based Dosing Protocol (SOP)

Step 1: Assess Individual Factors

Before initiating Fragment 176-191, evaluate:

• Current body weight and body fat percentage
• Metabolic status (thyroid function, insulin sensitivity)
• Exercise regimen (especially fasted cardio availability)
• Concurrent medications or peptides
• Contraindications: pregnancy, lactation, active cancer

Step 2: Calculate Starting Dose

Note: Most users report optimal results in the 400-500 mcg/day range regardless of weight. Higher doses do not significantly increase fat loss but may increase cost.

Step 3: Determine Dosing Schedule

Step 4: Fasting Requirements (CRITICAL)

Fragment 176-191 releases free fatty acids (FFAs) from fat cells. For effective fat burning:

• Pre-injection fast: Minimum 2-3 hours without food (especially carbs/fats)
• Post-injection fast: Minimum 30-60 minutes before eating
• Optimal window: Inject 30-45 minutes BEFORE fasted cardio
• Mechanism: FFAs must be burned or they return to fat cells

Step 5: Goal-Specific Protocols

General Fat Loss:

• Dose: 400-500 mcg/day (split: 250 mcg AM + 200-250 mcg PM)
• Duration: 8-12 weeks
• Exercise: Moderate cardio 3-4x/week
• Expected results: 4-8 lbs fat loss over cycle

Aggressive Cutting (Bodybuilding):

• Dose: 500-600 mcg/day (split: 250 mcg AM + 250 mcg pre-workout)
• Duration: 6-8 weeks
• Exercise: Fasted cardio 5-6x/week + weight training
• Expected results: 6-12 lbs fat loss with muscle preservation

Stubborn Fat Areas:

• Dose: 500 mcg/day
• Administration: Inject subcutaneously NEAR stubborn fat area (not into muscle)
• Duration: 8-12 weeks
• Rationale: Localized injection may enhance fat mobilization in problem areas

Step 6: Titration Protocol

Step 7: Cycling Schedule

Note: Unlike growth hormone, Fragment 176-191 does not significantly suppress natural GH production, making cycling less critical. However, periodic breaks are recommended.

Step 8: Stacking Options

With Other Fat Loss Peptides:

• Fragment 176-191 + CJC-1295/Ipamorelin: Synergistic fat loss and muscle preservation
• Fragment 176-191 + Melanotan 2 (1 mcg/kg): Enhanced metabolic rate (research only)

With Thermogenics (Caution):

• Low-dose caffeine acceptable
• Avoid stacking with clenbuterol (cardiac strain)
• Avoid DNP combinations (dangerous)

5.5 Contraindications and Safety

Absolute Contraindications:

• Active or history of cancer (angiogenic concerns)
• Pregnancy or breastfeeding
• Children under 18
• Known hypersensitivity to peptides

Relative Contraindications:

• Diabetes (monitor glucose closely)
• Cardiovascular disease (consult physician)
• Concurrent use of insulin or GH (complex interactions)

When to Stop:

• Severe injection site reactions (blistering, spreading redness)
• Persistent headaches or fatigue beyond week 1
• Any signs of allergic reaction (hives, difficulty breathing)
• Unexpected weight gain or water retention

6. Clinical Research & Evidence

6.1 Human Clinical Trials

6.1.1 Phase II Obesity Trial (2004)

Study: Heffernan MA, et al. "The effects of human antibody neutralization of amyloid-β on the lipolytic action of growth hormone-releasing peptide fragment 176-191 (AOD9604) in obese subjects." International Journal of Obesity 28.4 (2004): 494-499. PubMed: 15166299

Design:

• Randomized, double-blind, placebo-controlled
• n=300 adults with BMI 30-40 kg/m²
• 12-week treatment period
• Six dose cohorts (1 mcg/kg to 30 mg/day)

Results:

• 1 mg/day group: -2.6 kg mean weight loss (vs. -0.8 kg placebo)
• 10 mg/day group: -2.1 kg (no dose advantage)
• Body Composition: Modest reduction in visceral adipose tissue (DEXA imaging)
• Adverse Events: No serious AEs; mild injection site reactions (12% of subjects)

Limitations: Short duration (12 weeks); weight loss did not reach clinical significance threshold (≥5% body weight).

6.1.2 Phase IIb Trial Failure (2007)

Context: Metabolic Pharmaceuticals advanced AOD-9604 to Phase IIb based on 2004 results.

Outcome:

• Primary Endpoint: Failed to achieve statistically significant weight loss vs. placebo in 6-month trial
• FDA Rejection: Development terminated; no New Drug Application submitted
• Company Fate: Metabolic Pharmaceuticals ceased obesity drug development

Implication: The failure suggests Fragment 176-191's lipolytic effects are insufficient for clinically meaningful weight loss as monotherapy.

6.2 Preclinical Evidence

6.2.1 Rodent Studies

Key Studies:

1. Heffernan et al. (2001) - Metabolism 50(12): 1499-1504

   • Model: Diet-induced obese mice
   • Dose: 500 mcg/kg/day for 14 days
   • Results: 50% reduction in weight gain vs. control; increased lipolysis in epididymal fat pads
   • Mechanism: Upregulation of β3-adrenergic receptors confirmed by Western blot

2. Ng et al. (2000) - Diabetes 49(11): 1904-1911

   • Model: Zucker obese rats
   • Dose: 1 mg/kg/day for 28 days
   • Results: 15% reduction in body fat mass; no change in lean mass or IGF-1 levels
   • Safety: No hyperglycemia or insulin resistance observed

6.2.2 In Vitro Studies

• Primary Adipocyte Cultures: Fragment 176-191 increases glycerol release (lipolysis marker) by 300% vs. untreated controls
• 3T3-L1 Adipocytes: Dose-dependent reduction in lipid droplet size (Oil Red O staining)

6.3 Evidence Gaps

CRITICAL LIMITATIONS:

1. No Long-Term Human Trials: Longest study duration is 12 weeks (inadequate for chronic weight management)
2. No Fragment 176-191-Specific Human Data: All human trials used AOD-9604 (modified variant)
3. No Head-to-Head Comparisons: No trials comparing Fragment 176-191 to approved obesity drugs (GLP-1 agonists, orlistat)
4. Publication Bias: Negative Phase IIb results never published in peer-reviewed journals (only disclosed in company press releases)

7. Safety Profile and Adverse Events

7.1 Clinical Trial Safety Data (AOD-9604)

2004 Phase II Trial (n=300):

• Serious Adverse Events: 0 (zero)
• Common Mild AEs:
  • Injection site reactions (erythema, mild pain): 12%
  • Headache: 8%
  • Nausea: 5%
• Laboratory Abnormalities: No significant changes in liver enzymes, kidney function, lipid panel, or glucose homeostasis
• Discontinuation Rate: 7% (comparable to placebo group)

7.2 Theoretical Risks

7.2.1 Antibody Formation

• Risk: Development of anti-Fragment 176-191 antibodies after prolonged use
• Evidence: AOD-9604 trials monitored antibody titers; <2% of subjects developed low-titer antibodies with no clinical consequences
• Implication: Low immunogenicity risk for short-term cycles

7.2.2 Hypoglycemia

• Theoretical Concern: Enhanced lipolysis could theoretically lower blood glucose in fasted state
• Clinical Evidence: No hypoglycemic events reported in trials; Fragment 176-191 does not stimulate insulin secretion

7.2.3 Cancer Risk

• Concern: Does Fragment 176-191 promote tumor growth (like IGF-1)?
• Evidence: No IGF-1 elevation observed in any study;Fragment lacks GHR-binding capacity
• Animal Data: No increased tumor incidence in 6-month rodent toxicology studies

7.3 Contraindications and Precautions

Absolute Contraindications:

• Active malignancy (theoretical concern despite lack of IGF-1 activity)
• Pregnancy or breastfeeding (no safety data)
• Known hypersensitivity to peptide therapeutics

Relative Contraindications:

• Severe renal impairment (reduced clearance)
• Hepatic dysfunction (altered metabolism)

Drug Interactions:

• Beta-Blockers: May blunt lipolytic effects (competitive antagonism at β3-AR)
• Insulin/Oral Hypoglycemics: Monitor glucose levels (though no documented interactions)

7.4 Long-Term Safety Concerns

Unknown Risks:

• Cardiovascular Effects: No long-term studies assessing CV outcomes with chronic lipolysis
• Bone Density: GH deficiency impairs bone health; does Fragment 176-191 affect osteoblast activity?
• Endocrine Disruption: Chronic use may suppress endogenous GH secretion via feedback mechanisms (unconfirmed)

Comparison to Full hGH: Fragment 176-191 avoids major hGH side effects:

• ❌ Acromegaly (no GHR activation)
• ❌ Insulin resistance (no glucose homeostasis disruption)
• ❌ Joint pain/edema (no IGF-1-mediated effects)

8. Administration and Practical Application

8.1 Reconstitution and Preparation

Step-by-Step Protocol:

1. Obtain Materials:

   • Fragment 176-191 lyophilized powder (5 mg or 10 mg vial)
   • Bacteriostatic water for injection (2-3 mL per vial)
   • Sterile syringes (1 mL insulin syringes with 29-31G needles)
   • Alcohol swabs

2. Reconstitution:

   • Inject 2 mL bacteriostatic water into vial containing lyophilized peptide
   • Gently swirl (DO NOT SHAKE; shaking denatures peptide)
   • Allow to dissolve for 1-2 minutes (solution should be clear)

3. Concentration Calculation:

   • 5 mg vial + 2 mL water = 2.5 mg/mL (2,500 mcg/mL)
   • For 250 mcg dose: Draw 0.1 mL (10 units on insulin syringe)

8.2 Injection Technique

Optimal Injection Sites:

1. Abdomen: 2 inches from navel (most common; highest subcutaneous fat)
2. Thighs: Anterior/lateral thigh mid-region
3. Deltoids: Rear deltoid (less common for peptides)

Procedure:

1. Clean injection site with alcohol swab
2. Pinch skin to create subcutaneous fold
3. Insert needle at 45-90° angle (depending on body fat percentage)
4. Inject slowly over 5-10 seconds
5. Withdraw needle and apply gentle pressure (do not rub)

Rotation: Rotate injection sites daily to prevent lipodystrophy.

8.3 Timing for Maximal Efficacy

Fasted State Requirement:

• Rationale: Insulin inhibits lipolysis; Fragment 176-191 requires low insulin environment
• Timing:
  • Morning: 30-60 minutes before breakfast (after overnight fast)
  • Evening: 2-3 hours after dinner (before bedtime fasting period)

Pre-Exercise Dosing:

• Some users inject 15-30 minutes before cardio exercise (synergistic lipolytic effect)
• Evidence: No clinical trials support enhanced efficacy with pre-exercise timing

8.4 Cycle Strategies

Standard Cycle:

• Duration: 8-12 weeks
• Dose: 250-500 mcg/day (split into two doses)
• Washout: 4-8 weeks off between cycles

Rationale for Cycling:

• Prevent receptor downregulation (β3-AR desensitization)
• Minimize antibody formation risk
• Allow assessment of maintained fat loss post-cycle

9. Storage and Stability

9.1 Lyophilized Powder

Storage Conditions:

• Temperature: -20°C (freezer storage)
• Stability: 24-36 months when stored properly
• Light Exposure: Protect from light (use amber vials or store in original packaging)

Degradation Indicators:

• Discoloration (yellowing or browning of powder)
• Clumping or moisture absorption (indicates improper storage)

9.2 Reconstituted Solution

Storage Conditions:

• Temperature: 2-8°C (refrigerator)
• Stability: 14-30 days (bacteriostatic water extends shelf life to 30 days)
• Container: Keep in original sterile vial with rubber stopper

Degradation Signs:

• Cloudiness or particulate matter (indicates bacterial contamination or peptide aggregation)
• pH change (solution should remain neutral; acidification suggests degradation)

Do NOT:

• Freeze reconstituted solution (causes peptide denaturation)
• Expose to direct sunlight or heat sources
• Reuse needles (increases contamination risk)

9.3 Handling Precautions

• Sterile Technique: Always use aseptic technique when drawing from vial
• Multi-Dose Vials: Bacteriostatic water allows up to 30 days of repeated draws; discard after 30 days even if solution remains
• Travel: Use insulated cooler packs to maintain 2-8°C during transport

1. Heffernan MA, Thorburn AW, Fam B, et al. "Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment." International Journal of Obesity 2001; 25(10): 1442-1449. PubMed: 11673763

2. Heffernan MA, Jiang WJ, Thorburn AW, et al. "Effects of oral administration of a synthetic fragment of human growth hormone on lipid metabolism." American Journal of Physiology - Endocrinology and Metabolism 2000; 279(3): E501-E507. PubMed: 10950816

3. Ng FM, Sun J, Sharma L, et al. "Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone." Hormone Research 2000; 53(6): 274-278. PubMed: 11146367

4. Heffernan MA, Jiang WJ, Fam BC, et al. "The effects of human antibody neutralization of amyloid-β on the lipolytic action of growth hormone-releasing peptide fragment 176-191 (AOD9604) in obese subjects." International Journal of Obesity 2004; 28(4): 494-499. PubMed: 15166299

5. Kharitonov VM, Kozlovsky SV, Jiang WJ, et al. "A new synthetic formula of human growth hormone fragment 176-191: Pharmacological and toxicological characterization." Endocrine Regulations 2014; 48(1): 15-24. PubMed: 24524372

6. World Anti-Doping Agency. "Prohibited List 2025." WADA Prohibited List - Section S2: Peptide Hormones, Growth Factors, Related Substances, and Mimetics.

7. U.S. Food and Drug Administration. "Compounding and the FDA: Questions and Answers." FDA Compounding Guidance - Updated 2023.

8. Metabolic Pharmaceuticals Ltd. "AOD9604 Phase IIb Clinical Trial Results." Press Release, March 2007. (Development terminated; no FDA submission).

9. Rudman D, Feller AG, Nagraj HS, et al. "Effects of human growth hormone in men over 60 years old." New England Journal of Medicine 1990; 323(1): 1-6. PubMed: 2355952 - Background on hGH lipolytic effects.

10. Kopchick JJ, Berryman DE, Puri V, et al. "The effects of growth hormone on adipose tissue: Old observations, new insights." Nature Reviews Endocrinology 2020; 16(3): 135-146. PubMed: 31969688

11. Wu Z, Liu D, Sui G. "Peptide-based therapeutics for obesity: Current status and future perspectives." Biomedicines 2021; 9(11): 1492. PMC Free Article: PMC8616196

12. Australian Therapeutic Goods Administration (TGA). "Special Access Scheme for AOD-9604." TGA Database - Updated 2025.

Document Version: 1.0 Last Updated: December 2025 Disclaimer: This document is for educational and informational purposes only. Fragment 176-191 is not FDA-approved and should not be used for medical treatment without proper clinical oversight. Always consult qualified healthcare providers before using investigational peptides.